The fact sheet is being released as Canada awaits the launch of additional anticancer biosimilars.
Cancer Care Ontario (CCO), the cancer advisory organization for the government of Ontario, Canada, has released a new patient fact sheet for those starting or switching to biosimilars.
The fact sheet covers topics including the following:
The fact sheet is being released as Canada awaits the launch of additional anticancer biosimilars. Already approved and marketed in Canada is biosimilar trastuzumab (Ogivri). Approved but not yet marketed products include biosimilar rituximab (Truxima) and biosimilar bevacizumab (Zirabev).
Earlier this year, a report said Canada's use of biosimilars has been low relative to other countries because of a combination of factors, including limited awareness of clinical and scientific evidence supporting their use and strong efforts by brand-name biologic companies to retain market share.
The report, “A Prescription for Canada: Achieving Pharmacare for All,” contains 2 recommendations that pertain to the use of biosimilars. One recommendation says that there should be formulary management policies, including requiring biosimilar substitution and encouraging patients and providers to choose the most cost-effective therapies. Prescribers and patients will need better support via information that reinforces the safety, efficacy, and benefits of biosimilars, the report said.
The second recommendation says that the Canadian drug agency should also work to increase awareness about the equivalency of generics to brand-name drugs and the rationale for the greater use of generics and biosimilars in order to keep pharmaceutical care affordable.
In Canada, prescription drug coverage is split between public programs for those 65 or older, in long-term care, or without income, while private, employer-based coverage applies to all others. There are over 100 public prescription drug plans and over 100,000 private plans, all with their own premiums, copayments, deductibles, and annual limits.
In the spring, CCO partnered with the pan-Canadian Pharmaceutical Alliance to create a pan-Canadian Oncology Biosimilars Initiative, which aims to ensure appropriate implementation and cost-effective use of therapeutic oncology biosimilars across Canada.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.